
News|Articles|June 1, 2002
Moxifloxacin: a once-daily, fourth-generation fluoroquinolone antibiotic
Product Profile
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
ALK Testing Strategies and Navigating First-Line Treatment Options in Advanced NSCLC
2
How PBMs are tackling behavioral health
3
Most commercial plans cover SC and IV oncology therapies at parity
4
ALK-Positive NSCLC: Epidemiology, Prognosis, and the Critical Role of Biomarker Testing
5































